Skip to main content
. 2015 Oct 16;10(10):e0140700. doi: 10.1371/journal.pone.0140700

Table 3. Relationship between clinico-pathological characteristics and hr- HPV Positivity.

Characteristic Total Cases (n = 106) N (%) hr- HPV positive (n = 33) N (%) hr-HPV Negative (n = 73) N (%) Unadjusted OR [95%CI] P –value
Univariate analysis
Site
Oral cavity 86 (81.13) 24 (72.72) 62 (84.93) 4.73[0.17–1.28] 1.40
Laryngeal 9 (8.49) 2 (6.06) 7 (9.58) 0.61[0.11–3.10] 0.55
Hypopharyngeal 3 (2.83) 2 (6.06) 1 (1.37) 4.64[0.40–53.1] 0.18
Oropharyngeal 5 (4.71) 5 (15.15) 0 (0.00) - <0.01*
Nose and PNS 3 (2.83) 0 (0.00) 3 (4.10) - 0.24
TNM Tumor stage
II 15 (14.15) 3 (9.09) 12 (16.45) 1.0 (referent)
III 26 (24.52) 6 (18.18) 20 (27.39) 1.20 [0.20–7.55] 1.00
IVA 59 (55.66) 24 (72.73) 35 (47.94) 2.74[0.62–13.81] 0.13
IVB 6 (5.66) 0 (0.00) 6 (8.21) - 0.52
Histology
Verrucous Carcinoma 8 (7.54) 2 (6.06) 6 (8.21) 1.0 (referent)
Squamous Cell Carcinoma 91 (85.85) 30 (90.91) 61 (83.56) 1.48[0.25–11.31] 1.00
Others 7 (6.60) 1 (3.03) 6 (8.21) 0.50[0.01–11.02] 1.00
Morphology
Well Differentiated 74 (69.81) 21 (63.63) 53 (72.60) 1.0 (referent)
Moderate Differentiated 22 (20.75) 8 (24.24) 14 (19.17) 1.44[0.47–4.38] 0.47
Poor Differentiated 10 (9.44) 4 (12.12) 6 (8.21) 1.68[0.35–7.74] 0.38

* Statistically Significant OR = odds ratio; CI = confidence interval;

Reference group for OR calculation